| Title | Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer |
| Authors | Zhang, Xinyan Feng, Jie Ye, Xue Yao, Yu Zhou, Ping Chen, Xiaoxin |
| Affiliation | N Carolina Cent Univ, Canc Res Program, Julius L Chambers Biomed Biotechnol Res Inst, Durham, NC 27707 USA. Peking Univ, Peoples Hosp, Gynecol Oncol Ctr, Beijing 100044, Peoples R China. N Carolina Cent Univ, Canc Res Program, Julius L Chambers Biomed Biotechnol Res Inst, 700 George St, Durham, NC 27707 USA. |
| Keywords | immunocytokine interleukin 2 ovarian cancer SINGLE-CHAIN FV MONOCLONAL-ANTIBODY PROSTATE-CANCER INTERLEUKIN-2 CARCINOMA THERAPY FUSION ANTIGENS |
| Issue Date | 2006 |
| Publisher | gynecologic oncology |
| Citation | GYNECOLOGIC ONCOLOGY.2006,103,(3),848-852. |
| Abstract | Objectives. The purpose of this study was to develop an immunocytokine for immunotherapy of human ovarian cancer. Methods. The single-chain Fv of a monoclonal antibody, COC183B2, specific for an ovarian carcinoma-associated antigen (OC183B2), was genetically fused with the coding sequence of interleukin 2 (IL-2). The fusion protein, also called immunocytokine, IL-2-183B2scFv, was expressed in CHO cells and examined for its specificity and biological function. Results. The immunocytokine, IL-2-183B2scFv, retained the functions of both the antibody and IL-2. It was able to target IL-2 to tumor cells that overexpress OC183B2, and stimulate the proliferation of an IL-2-dependent cell line, CTLL-2. Conclusions. The IL-2-183B2scFv maintains the functions of both IL-2 and antibody. It can be potentially used for immunotherapy of ovarian cancer by delivering a high concentration of IL-2 to OC183B2-expressing ovarian cancer cells. (c) 2006 Elsevier Inc. All rights reserved. |
| URI | http://hdl.handle.net/20.500.11897/198807 |
| ISSN | 0090-8258 |
| DOI | 10.1016/j.ygyno.2006.05.016 |
| Indexed | SCI(E) PubMed |
| Appears in Collections: | 人民医院 |
